NLRP3 inflammasome expression in idiopathic pulmonary fibrosis and rheumatoid lung

European Respiratory Journal

Volumn 47, Issue 3, 2016, Pages 910-918

  Lasithiotaki, Ismini ^a   Giannarakis, Ioannis ^a,b   Tsitoura, Eliza ^a   Samara, Katerina D ^a   Margaritopoulos, George A ^a   Choulaki, Christiana ^a   Vasarmidi, Eirini ^a   Tzanakis, Nikolaos ^a,b   Voloudaki, Argyro ^b   Sidiropoulos, Prodromos ^a   Siafakas, Nikolaos M ^b   Antoniou, Katerina M ^a,b  

^a UNIVERSITY OF CRETE   (Greece)

^b UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; CRYOPYRIN; INFLAMMASOME; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; TUMOR NECROSIS FACTOR ALPHA; IL11RA PROTEIN, HUMAN; INTERLEUKIN 11 RECEPTOR ALPHA; NLRP3 PROTEIN, HUMAN;

ADULT; ARTICLE; BRONCHOALVEOLAR LAVAGE FLUID; CELL CULTURE; CELL LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME ACTIVATION; FEMALE; FIBROSING ALVEOLITIS; HUMAN; HUMAN CELL; INTERSTITIAL PNEUMONIA; LUNG ALVEOLUS MACROPHAGE; MACROPHAGE CULTURE; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RHEUMATOID ARTHRITIS; UPREGULATION; AGED; GREECE; INTERSTITIAL LUNG DISEASE; LUNG; MACROPHAGE; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; SIGNAL TRANSDUCTION; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ARTHRITIS, RHEUMATOID; BRONCHOALVEOLAR LAVAGE FLUID; FEMALE; GREECE; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; INFLAMMASOMES; INTERLEUKIN-11 RECEPTOR ALPHA SUBUNIT; INTERLEUKIN-18; LIPOPOLYSACCHARIDES; LUNG; LUNG DISEASES, INTERSTITIAL; MACROPHAGES; MALE; MIDDLE AGED; NLR FAMILY, PYRIN DOMAIN-CONTAINING 3 PROTEIN; SIGNAL TRANSDUCTION;

EID: 84959891521     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/13993003.00564-2015     Document Type: Article

References (40)

1. Vancheri C, du Bois RM. A progression-free end-point for idiopathic pulmonary fibrosis trials: lessons from cancer. Eur Respir J 2013; 41: 262-269.
2. Margaritopoulos GA, Romagnoli M, Poletti V, et al. Recent advances in the pathogenesis and clinical evaluation of pulmonary fibrosis. Eur Respir Rev 2012; 21: 48-56.
3. Wuyts WA, Agostini C, Antoniou KM, et al. The pathogenesis of pulmonary fibrosis: a moving target. Eur Respir J 2013; 41: 1207-1218.
4. Wuyts WA, Antoniou KM, Borensztajn K, et al. Combination therapy: the future of management for idiopathic pulmonary fibrosis? Lancet Respir Med 2014; 2: 933-942.
5. Antoniou KM, Margaritopoulos G, Economidou F, et al. Pivotal clinical dilemmas in collagen vascular diseases associated with interstitial lung involvement. Eur Respir J 2009; 33: 882-896.
6. Cottin V. Pragmatic prognostic approach of rheumatoid arthritis-associated interstitial lung disease. Eur Respir J 2010; 35: 1206-1208.
7. Hunninghake GM. A new hope for idiopathic pulmonary fibrosis. N Engl J Med 2014; 370: 2142-2143.
8. Antoniou KM, Walsh SL, Hansell DM, et al. Smoking-related emphysema is associated with idiopathic pulmonary fibrosis and rheumatoid lung. Respirology 2013; 18: 1191-1196.
9. Sidiropoulos PI, Goulielmos G, Voloudakis GK, et al. Inflammasomes and rheumatic diseases: evolving concepts. Ann Rheum Dis 2008; 67: 1382-1389.
10. Artlett CM. Inflammasomes in wound healing and fibrosis. J Pathol 2013; 229: 157-167.
11. Antoniou KM, Margaritopoulos GA, Giannarakis I, et al. Adult onset Still's disease: a case report with a rare clinical manifestation and pathophysiological correlations. Case Rep Med 2013; 2013: 981232.
12. Hogaboam CM, Murray L, Martinez FJ. Epigenetic mechanisms through which Toll-like receptor-9 drives idiopathic pulmonary fibrosis progression. Proc Am Thorac Soc 2012; 9: 172-176.
13. Lasithiotaki I, Antoniou KM, Vlahava VM, et al. Detection of herpes simplex virus type-1 in patients with fibrotic lung diseases. PLoS One 2011; 6: e27800.
14. Aumiller V, Balsara N, Wilhelm J, et al. WNT/beta-catenin signaling induces IL-1beta expression by alveolar epithelial cells in pulmonary fibrosis. Am J Respir Cell Mol Biol 2013; 49: 96-104.
15. Dostert C, Petrilli V, Van Bruggen R, et al. Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica. Science 2008; 320: 674-677.
16. Xu JF, Washko GR, Nakahira K, et al. Statins and pulmonary fibrosis: the potential role of NLRP3 inflammasome activation. Am J Respir Crit Care Med 2012; 185: 547-556.
17. Kong H, Wang Y, Zeng X, et al. Involvement of NLRP3 inflammasome in rituximab-induced interstitial lung disease: a case report. J Clin Pharm Ther 2014; 39: 691-694.
18. Artlett CM, Sassi-Gaha S, Rieger JL, et al. The inflammasome activating caspase 1 mediates fibrosis and myofibroblast differentiation in systemic sclerosis. Arthritis Rheum 2011; 63: 3563-3574.
19. Simpson JL, Phipps S, Baines KJ, et al. Elevated expression of the NLRP3 inflammasome in neutrophilic asthma. Eur Respir J 2014; 43: 1067-1076.
20. Dolinay T, Kim YS, Howrylak J, et al. Inflammasome-regulated cytokines are critical mediators of acute lung injury. Am J Respir Crit Care Med 2012; 185: 1225-1234.
21. Di Stefano A, Caramori G, Barczyk A, et al. Innate immunity but not NLRP3 inflammasome activation correlates with severity of stable COPD. Thorax 2014; 69: 516-524.
22. Churg A, Zhou S, Wang X, et al. The role of interleukin-1beta in murine cigarette smoke-induced emphysema and small airway remodeling. Am J Respir Cell Mol Biol 2009; 40: 482-490.
23. Eltom S, Stevenson CS, Rastrick J, et al. P2X7 receptor and caspase 1 activation are central to airway inflammation observed after exposure to tobacco smoke. PloS One 2011; 6: e24097.
24. Choulaki C, Papadaki G, Repa A, et al. Enhanced activity of NLRP3 inflammasome in peripheral blood cells of patients with active rheumatoid arthritis. Arthritis Res Ther 2015; 17: 257.
25. Netea MG, Nold-Petry CA, Nold MF, et al. Differential requirement for the activation of the inflammasome for processing and release of IL-1beta in monocytes and macrophages. Blood 2009; 113: 2324-2335.
26. Netea MG, van de Veerdonk FL, van der Meer JW, et al. Inflammasome-independent regulation of IL-1-family cytokines. Annu Rev Immunol 2015; 33: 49-77.
27. Moodley YP, Misso NL, Scaffidi AK, et al. Inverse effects of interleukin-6 on apoptosis of fibroblasts from pulmonary fibrosis and normal lungs. Am J Respir Cell Mol Biol 2003; 29: 490-498.
28. De Lauretis A, Sestini P, Pantelidis P, et al. Serum interleukin 6 is predictive of early functional decline and mortality in interstitial lung disease associated with systemic sclerosis. J Rheumatol 2013; 40: 435-446.
29. Shulgina L, Cahn AP, Chilvers ER, et al. Treating idiopathic pulmonary fibrosis with the addition of co-trimoxazole: a randomised controlled trial. Thorax 2013; 68: 155-162.
30. Wang LQ, Liu JC, Chen CL, et al. Regulation of primordial follicle recruitment by cross-talk between the Notch and phosphatase and tensin homologue (PTEN)/AKT pathways. Reprod Fertil Dev 2014; in press [DOI: 10.1071/RD14212].
31. Molyneaux PL, Cox MJ, Willis-Owen SA, et al. The role of bacteria in the pathogenesis and progression of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2014; 190: 906-913.
32. Nakahira K, Haspel JA, Rathinam VA, et al. Autophagy proteins regulate innate immune responses by inhibiting the release of mitochondrial DNA mediated by the NALP3 inflammasome. Nat Immunol 2011; 12: 222-230.
33. van der Burgh R, Nijhuis L, Pervolaraki K, et al. Defects in mitochondrial clearance predispose human monocytes to interleukin-1beta hypersecretion. J Biol Chem 2014; 289: 5000-5012.
34. Margaritopoulos GA, Tsitoura E, Tzanakis N, et al. Self-eating: friend or foe? The emerging role of autophagy in idiopathic pulmonary fibrosis. BioMed Res Int 2013; 2013: 420497.
35. Araya J, Kojima J, Takasaka N, et al. Insufficient autophagy in idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 2013; 304: L56-L69.
36. Bueno M, Lai YC, Romero Y, et al. PINK1 deficiency impairs mitochondrial homeostasis and promotes lung fibrosis. J Clin Invest 2015; 125: 521-538.
37. Kahloon RA, Xue J, Bhargava A, et al. Patients with idiopathic pulmonary fibrosis with antibodies to heat shock protein 70 have poor prognoses. Am J Respir Crit Care Med 2013; 187: 768-775.
38. Keir GJ, Maher TM, Hansell DM, et al. Severe interstitial lung disease in connective tissue disease: rituximab as rescue therapy. Eur Respir J 2012; 40: 641-648.
39. Herazo-Maya JD, Noth I, Duncan SR, et al. Peripheral blood mononuclear cell gene expression profiles predict poor outcome in idiopathic pulmonary fibrosis. Sci Transl Med 2013; 5: 205ra136.
40. Wynn TA. Integrating mechanisms of pulmonary fibrosis. J Exp Med 2011; 208: 1339-1350.